tbuckley/cabot-search huggingface dataset:
A narrative review on the use of autologous platelet concentrates during alveolar bone augmentation: Horizontal (simultaneous/staged) &amp; vertical (simultaneous/staged)
Authors: J. Blanco, J. Caramês, M. Quirynen
Journal: Periodontology 2000 (2024)

This review aimed to answer the general question of whether autologous platelet concentrates (APCs, an autologous blood-derivative) can improve the outcome of alveolar bone augmentation. Three clinical scenarios were assessed: horizontal/vertical bone augmentation in combination with implant placement (simultaneous approach), horizontal bone augmentation in a staged approach, and vertical bone augmentation in a staged approach. An electronic literature search strategy was conducted for each review from the outset to July 1st, 2023. The titles and abstracts (when available) of all identified studies were screened and imported into a database. If articles appeared to meet the inclusion criteria or their title and abstract had insufficient data, the full text was obtained to make the final decision. All studies that met the inclusion criteria underwent data extraction. Moreover, the references of the identified papers were screened for additional studies. After title and abstract screening and selection criteria application, 14 clinical studies were included for the qualitative analysis: seven for horizontal/vertical bone augmentation in a simultaneous approach, five for horizontal bone augmentation in a staged approach, and two for vertical bone augmentation in a staged approach. There is scarce literature regarding the added value of APCs in bone augmentation, and most studies had small sample sizes, a lack of standardized protocols, and different outcome variables, which makes comparisons between studies difficult. Out of the 14 studies, four were well-designed randomized clinical trials, where we could find better results for the APCs groups. Most studies, particularly comparative and well-designed studies, demonstrated beneficial and promising results of using APCs in alveolar bone augmentation. However, before high-level evidence-based conclusions can be drawn, more randomized clinical trials must compare the benefits of adding APCs to the gold-standard approach.
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non–muscle-invasive Bladder Cancer
Authors: Irene J Beijert, Oskar Hagberg, Truls Gårdmark, Lars Holmberg, Christel Häggström, Allan Johnston, Matthew Trail, Sami Hamid, Barend A Dreyer, Luisa Padovani, Roberta Garau, Rami Hasan, Imran Ahmad, David Hendry, Eva M Compérat, Maximilian Burger, Morgan Rouprêt, Paolo Gontero, Maria J Ribal, Theo H van der Kwast, Marko Babjuk, Richard J Sylvester, Paramananthan Mariappan, Fredrik Liedberg, Bas W G van Rhijn
Journal: European Urology (2024)

Grade is an important determinant of progression in non-muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1: hazard ratio [HR] = 1.92; cohort 2: HR = 2.51, and cohort 3: HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers.
Comparison of postoperative inflammatory response between natural orifice specimen extraction surgery and conventional laparoscopy in the treatment of colorectal cancer: a meta-analysis and systematic review
Authors: Xinyue Liu, Xinzhu Yuan, Peilin Ye, Jie Yang, Ka Li
Journal: International Journal of Surgery (2024)

Purpose: Natural orifice specimen extraction surgery (NOSES) has attracted attention because of its minimal invasiveness. This meta-analysis compared inflammatory response profiles and infectious complications between colorectal cancer (CRC) patients treated with NOSES and those treated with conventional laparoscopy (CL). Methods: Seven medical databases were searched up to February 2024.We included studies that examined changes in the inflammatory response and outcomes in the patients after NOSES surgery. The Cochrane tool and Newcastle-Ottawa Scale (NOS) were used to evaluate the quality of the studies. Pooled standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using either fixed- or random-effects models. Review Manager 5.4 (RevMan 5.4) and the R project were used for the meta-analysis. Results: This meta-analysis included 22 studies. Pooled analyses revealed lower tumor necrosis factor-α (TNF-α) levels (SMD=-1.34,95% CI [-2.43, -0.25]; Z=2.40, P =0.02 and SMD =-1.49,95% CI [-2.15, -0.82]; Z=4.36, P &lt;0.0001) and C reactive protein (CRP) levels (SMD=-0.56, 95% CI [-4.17, -2.50]; Z=2.19, P =0.03 and SMD =-1.24,95% CI[-1.77, -0.71]; Z=4.56, P &lt;0.00001) on postoperative day 1 (POD1) and postoperative day 3 (POD3) for NOSES than for CL. Pooled analysis revealed significantly lower interleukin-6 (IL-6) levels in the NOSES group (SMD=-1.88,95% CI [-2.84, -0.93]; Z=3.88, P =0.0001) on POD3. There were no significant differences in white blood cell (WBC) count, procalcitonin (PCT) levels or the incidence of infectious complications between the two groups. Conclusions: NOSES has a superior inflammatory profile and does not increase the incidence of postoperative infectious diseases. The reported results should be validated in a larger population of CRC patients.
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
Authors: Maria Buti, Jeong Heo, Yasuhito Tanaka, Pietro Andreone, Masanori Atsukawa, Joaquín Cabezas, Eric Chak, Carla S. Coffin, Kei Fujiwara, Natalya Gankina, Stuart C. Gordon, Ewa Janczewska, Atsumasa Komori, Pietro Lampertico, Stuart McPherson, Vyacheslav Morozov, Robert Plesniak, Sébastien Poulin, Pablo Ryan, Olga Sagalova, Guoping Sheng, Natalya Voloshina, Qing Xie, Hyung Joon Yim, Susan Dixon, Melanie Paff, Leigh Felton, Maximilian Lee, Thomas Greene, Jessica Lim, Divya Lakshminarayanan, Grant McGonagle, Helene Plein, Amir S. Youssef, Rob Elston, Stuart Kendrick, Dickens Theodore
Journal: Journal of Hepatology (2024)
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Authors: D. Ciardiello, L. Boscolo Bielo, S. Napolitano, E. Martinelli, T. Troiani, A. Nicastro, T.P. Latiano, P. Parente, E. Maiello, A. Avallone, N. Normanno, S. Pisconti, C. Nisi, R. Bordonaro, A.E. Russo, E. Tamburini, I. Toma, C. Lotesoriere, S. Vallarelli, M.G. Zampino, N. Fazio, G. Curigliano, F. De Vita, F. Ciardiello, G. Martini, Davide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, Erika Martinelli, Teresa Troiani, Antonella Nicastro, Tiziana Pia Latiano, Paola Parente, Evaristo Maiello, Antonio Avallone, Nicola Normanno, Salvatore Pisconti, Claudia Nisi, Roberto Bordonaro, Alessia Erika Russo, Emiliano Tamburrini, Ilaria Toma, Claudio Lotesoriere, Simona Vallarelli, Maria Giulia Zampino, Nicola Fazio, Giuseppe Curigliano, Fortunato Ciardiello, Giulia Martini, Sara Lonardi, Chiara Cremolini, Carlo Garufi, Pierosandro Tagliaferri, Giampaolo Tortora, Filippo Pietrantonio, Antonio Febbraro, Gerardo Rosati, Silvana Leo, Oronzo Brunetti, Rosanna Berardi, Saverio Cinieri, Mario Scartozzi, Alberto Zaniboni, Giancarlo Paoletti
Journal: Annals of Oncology (2024)
Early-life malnutrition exposure associated with higher osteoporosis risk in adulthood: a large-scale cross-sectional study
Authors: Hongbin Xu, Haitao Zhang, Remila Aimaiti, Chunchun Yuan, Feihong Cai, Hongyu Wang, Jiangxun Ji, Junhao Liang, Jiarui Cui, Jing Wang, Bing Shu, Hao Xu, Qianqian Liang, Qi Shi, Qi Sun, Rui Fang, Dezhi Tang, Yongjun Wang
Journal: International Journal of Surgery (2024)

Evidence on the association between early-life malnutrition exposure at different developmental stages and the subsequent risk of osteoporosis and fractures in adulthood remains sparse and equivocal. This study sought to elucidate the relationship between malnutrition exposure in early life and the occurrence of osteoporosis and fractures later in life.
A cross-comparison of different extreme value modeling techniques for traffic conflict-based crash risk estimation
Authors: Depeng Niu, Tarek Sayed, Chuanyun Fu, Fred Mannering
Journal: Analytic Methods in Accident Research (2024)

Extreme Value Theory (EVT) models have recently gained increasing popularity for crash risk estimation using traffic conflict data. Extreme value modeling consists of two fundamental approaches: the block maxima approach and the peak-over-threshold approach, each with several variants. However, a comprehensive comparison of these two approaches and their variants in crash risk estimation is lacking. This study bridges this gap by comparing different extreme value modeling techniques and evaluating their performance in estimating crash frequencies. Within a non-stationary Bayesian hierarchical modeling framework, the analyzed models include the block maxima model, the r largest order statistic model, and the peak-over-threshold model with the fixed and dynamic threshold, across univariate and bivariate traffic conflict cases. The analysis utilizes modified time-to-collision and post-encroachment time conflict indicator data collected from four signalized intersections in the City of Surrey, British Columbia, Canada. The results show that incorporating additional order statistics in the r largest order statistic model improves predictive performance, particularly with limited extreme conflict samples. Moreover, employing the dynamic threshold within the peak-over-threshold model enhances model goodness-of-fit and yields more accurate crash frequency estimates compared to using the fixed threshold. While the performance of the block maxima and peak-over-threshold models varies with the selected conflict indicator in the univariate case, the bivariate peak-over-threshold model with the dynamic threshold exhibits superior overall prediction accuracy over the corresponding block maxima model. This is likely due to the effectiveness of the dynamic threshold in precisely identifying truly critical extreme conflicts.
How to develop a controlled human infection model for Clostridioides difficile
Authors: Annefleur D.O. Hensen, Maria J.G.T. Vehreschild, Dale N. Gerding, Oleg Krut, Wilbur Chen, Vincent B. Young, Saul Tzipori, Philipp Solbach, Malick Mahdi Gibani, Christopher Chiu, Sigrid C.J. de Keersmaecker, Dileep Dasyam, Sandra Morel, Jeanne-Marie Devaster, Nicoletta Corti, Ed J. Kuijper, Meta Roestenberg, Wiep Klaas Smits
Journal: Clinical Microbiology and Infection (2024)

Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges because of antibiotic resistance and high relapse rates. Faecal microbiota transplantation is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however, the exact components conferring colonization resistance are unknown, hampering its translation to a medicinal product. The development of novel products independent of antibiotics, which increase colonization resistance or induce protective immune mechanisms is urgently needed.
Gerotherapeutics: Aging Mechanism-based Pharmaceutical and Behavioral Interventions to Reduce Cancer Racial and Ethnic Disparities
Authors: Jeanne S Mandelblatt, Michael H Antoni, Traci N Bethea, Steve Cole, Barry I Hudson, Frank J Penedo, Amelie G Ramirez, G William Rebeck, Swarnavo Sarkar, Ann G Schwartz, Erica K Sloan, Yun-Ling Zheng, Judith E Carroll, Mina S Sedrak
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract The central premise of this article is that a portion of the established relationships between social determinants of health and racial and ethnic disparities in cancer morbidity and mortality is mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions (“gerotherapeutics”) to differentially improve the health of cancer survivors from minority populations and reduce cancer disparities. These hypotheses are based on evidence that lifelong differences in adverse social determinants of health contribute to disparities in rates of biological aging (“social determinants of aging”), with individuals from minoritized groups experiencing accelerated aging (ie, a steeper slope or trajectory of biological aging over time relative to chronological age) more often than individuals from nonminoritized groups. Acceleration of biological aging can increase the risk, age of onset, aggressiveness, and stage of many adult cancers. There are also documented negative feedback loops whereby the cellular damage caused by cancer and its therapies act as drivers of additional biological aging. Together, these dynamic intersectional forces can contribute to differences in cancer outcomes between survivors from minoritized vs nonminoritized populations. We highlight key targetable biological aging mechanisms with potential applications to reducing cancer disparities and discuss methodological considerations for preclinical and clinical testing of the impact of gerotherapeutics on cancer outcomes in minoritized populations. Ultimately, the promise of reducing cancer disparities will require broad societal policy changes that address the structural causes of accelerated biological aging and ensure equitable access to all new cancer control paradigms.
Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome
Authors: Suchira Gallage, Elaine E. Irvine, Jose Efren Barragan Avila, Virinder Reen, Silvia M. A. Pedroni, Imanol Duran, Vikas Ranvir, Sanjay Khadayate, Joaquim Pombo, Sharon Brookes, Danijela Heide, Gopuraja Dharmalingham, Agharul I. Choudhury, Indrabahadur Singh, Nicolás Herranz, Santiago Vernia, Mathias Heikenwalder, Jesús Gil, Dominic J. Withers
Journal: Nature Aging (2024)

Abstract Inhibition of S6 kinase 1 (S6K1) extends lifespan and improves healthspan in mice, but the underlying mechanisms are unclear. Cellular senescence is a stable growth arrest accompanied by an inflammatory senescence-associated secretory phenotype (SASP). Cellular senescence and SASP-mediated chronic inflammation contribute to age-related pathology, but the specific role of S6K1 has not been determined. Here we show that S6K1 deletion does not reduce senescence but ameliorates inflammation in aged mouse livers. Using human and mouse models of senescence, we demonstrate that reduced inflammation is a liver-intrinsic effect associated with S6K deletion. Specifically, we show that S6K1 deletion results in reduced IRF3 activation; impaired production of cytokines, such as IL1β; and reduced immune infiltration. Using either liver-specific or myeloid-specific S6K knockout mice, we also demonstrate that reduced immune infiltration and clearance of senescent cells is a hepatocyte-intrinsic phenomenon. Overall, deletion of S6K reduces inflammation in the liver, suggesting that suppression of the inflammatory SASP by loss of S6K could underlie the beneficial effects of inhibiting this pathway on healthspan and lifespan.
The genetic landscape of neuro-related proteins in human plasma
Authors: Linda Repetto, Jiantao Chen, Zhijian Yang, Ranran Zhai, Paul R. H. J. Timmers, Xiao Feng, Ting Li, Yue Yao, Denis Maslov, Anna Timoshchuk, Fengyu Tu, Emma L. Twait, Sebastian May-Wilson, Marisa D. Muckian, Bram P. Prins, Grace Png, Charles Kooperberg, Åsa Johansson, Robert F. Hillary, Eleanor Wheeler, Lu Pan, Yazhou He, Sofia Klasson, Shahzad Ahmad, James E. Peters, Arthur Gilly, Maria Karaleftheri, Emmanouil Tsafantakis, Jeffrey Haessler, Ulf Gyllensten, Sarah E. Harris, Nicholas J. Wareham, Andreas Göteson, Cecilia Lagging, Mohammad Arfan Ikram, Cornelia M. van Duijn, Christina Jern, Mikael Landén, Claudia Langenberg, Ian J. Deary, Riccardo E. Marioni, Stefan Enroth, Alexander P. Reiner, George Dedoussis, Eleftheria Zeggini, Sodbo Sharapov, Yurii S. Aulchenko, Adam S. Butterworth, Anders Mälarstig, James F. Wilson, Pau Navarro, Xia Shen
Journal: Nature Human Behaviour (2024)
Ebola disease outbreak caused by the Sudan virus in Uganda, 2022: a descriptive epidemiological study
Authors: Zainah Kabami, Alex R Ario, Julie R Harris, Mackline Ninsiima, Sherry R Ahirirwe, Jane R Aceng Ocero, Diana Atwine, Henry G Mwebesa, Daniel J Kyabayinze, Allan N Muruta, Atek Kagirita, Yonas Tegegn, Miriam Nanyunja, Saudah N Kizito, Daniel Kadobera, Benon Kwesiga, Samuel Gidudu, Richard Migisha, Issa Makumbi, Daniel Eurien, Peter J Elyanu, Alex Ndyabakira, Helen Nelly Naiga, Jane F Zalwango, Brian Agaba, Peter C Kawungezi, Marie G Zalwango, Patrick King, Brenda N Simbwa, Rebecca Akunzirwe, Mercy W Wanyana, Robert Zavuga, Thomas Kiggundu
Journal: The Lancet Global Health (2024)
Leukaemia, lymphoma, and multiple myeloma mortality after low-level exposure to ionising radiation in nuclear workers (INWORKS): updated findings from an international cohort study
Authors: Klervi Leuraud, Dominique Laurier, Michael Gillies, Richard Haylock, Kaitlin Kelly-Reif, Stephen Bertke, Robert D Daniels, Isabelle Thierry-Chef, Monika Moissonnier, Ausrele Kesminiene, Mary K Schubauer-Berigan, David B Richardson
Journal: The Lancet Haematology (2024)
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial
Authors: Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman
Journal: The Lancet Respiratory Medicine (2024)
Local Delivery of Platelet-Derived Factors Mitigates Ischemia and Preserves Ovarian Function through Angiogenic Modulation : A Personalized Regenerative Strategy for Fertility Preservation
Authors: Nanum Chung, Chungmo Yang, Heeseon Yang, Jungwoo Shin, Chae Young Song, Hyewon Min, Ji Hyang Kim, Kangwon Lee, Jung Ryeol Lee
Journal: Biomaterials (2024)
A Dendritic Cell-Recruiting, Antimicrobial Blood Clot Hydrogel for Melanoma Recurrence Prevention and Infected Wound Management
Authors: Wen-Shang Liu, Zheng-Mao Lu, Xiao-Hui Pu, Xin-Ying Li, Hui-Qi Zhang, Zhuan-Zhuan Zhang, Xin-Yi Zhang, Te Shi, Xiang-He Jiang, Jing-Sheng Zhou, Xuan Zhou, Zhong-Yuan Xin, Mei-Gui Li, Jing Yuan, Cui-Min Chen, Xiao-Wei Zhang, Jie Gao, Meng Li
Journal: Biomaterials (2024)
β-BLOCKERS LOWER FIRST DECOMPENSATION IN PATIENTS WITH CIRRHOSIS AND ENDURING PORTAL HYPERTENSION AFTER ETIOLOGICAL TREATMENT
Authors: Laura Turco, Madalina-Gabriela Taru, Giovanni Vitale, Horia Stefanescu, Federica Mirici Cappa, Sonia Berardi, Anna Baldan, Roberto Di Donato, Paolo Pianta, Vittoria Vero, Luca Vizioli, Lucia Maria Procopciuc, Bogdan Procopet, Maria Cristina Morelli, Fabio Piscaglia
Journal: Clinical Gastroenterology and Hepatology (2024)

Background and AimsNonselective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ≥10 mm Hg) with active etiology. Our aim was to examine the effect of NSBBs on first decompensation occurrence in patients with cirrhosis and enduring CSPH after etiological treatment.MethodsPatients with compensated cirrhosis and clinical evidence of CSPH (gastroesophageal varices [GEVs] and/or spontaneous portosystemic collaterals [SPSSs]) after 2 years from etiological treatment. The primary endpoint was first decompensation (occurrence of variceal bleeding, ascites, or hepatic encephalopathy) in patients on NSBBs vs off NSBBs.ResultsThe final cohort included 406 patients. Baseline characteristics of patients on NSBBs (n = 187) and off NSBBs (n = 219) were comparable, except for signs of portal hypertension that were more pronounced in the on-NSBB group. During a mean follow-up of 32 months, 127 (31%) patients decompensated, with ascites being the most common (77%) decompensating event. Decompensation rates were lower in patients on NSBBs (16% vs 44%; P < .0001). The benefit of NSBBs on decompensation was maintained in patients with small GEVs (17% vs 43%; P < .0001), in those with spontaneous portosystemic shunt only (8% vs 43%; P = .003), and in each different etiology, including hepatitis C virus–cured cirrhosis (9% vs 32%; P < .0001). At Cox regression analysis, hemoglobin, Child-Pugh, Model for End-Stage Liver Disease–Sodium, diabetes at baseline, and previous bacterial infections were independent predictors of decompensation, while NSBB use had a protective effect (hazard ratio, 0.32; 95% confidence interval, 0.20–0.49; P < .0001). NSBB use significantly reduced bacterial infection rates (hazard ratio, 0.36; 95% confidence interval, 0.22–0.58; P < .0001).ConclusionNSBBs decrease the risk of first decompensation in patients with cirrhosis and enduring CSPH after etiological treatment.Graphical abstract
High Diagnostic Value of Transient Elastography for Advanced Fibrosis and Cirrhosis in Patients With Chronic Hepatitis Delta
Authors: Dominique Roulot, Ségolène Brichler, Richard Layese, Louis D’alteroche, Nathalie Ganne-Carrie, Christiane Stern, Antonio Saviano, Vincent Leroy, Françoise Roudot-Thoraval, Victor De Ledinghen, Véronique Loustaud-Ratti, Christine Silvain, Souad Benali, Patrick Ingiliz, Martial Gouton, Dominique Guyader, Bruno Roche, Olivier Chazouillères, Tarik Asselah, Marianne Ziol
Journal: Clinical Gastroenterology and Hepatology (2024)
Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn’s disease
Authors: Joana Revés, Agnes Fernandez-Clotet, Ingrid Ordás, Anthony Buisson, Maëva Bazoge, Constance Hordonneau, Pierre Ellul, Melvin D’Anastasi, Ainara Elorza, Marta Aduna, Iago Rodríguez-Lago, Inês Sousa Lajas, Ana Raimundo, Paulo J.G. Bettencourt, Gonçalo Freire, Pedro Sousa, Ana Primitivo, Ivo Delgado, Jordi Rimola, Joana Torres
Journal: Clinical Gastroenterology and Hepatology (2024)
Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival - A National Analysis
Authors: Lucia Parlati, Charlotte Mouliade, Eric Nguyen Khac, Mathis Collier, Stylianos Tzedakis, Samir Bouam, Anoisia Courtois, Marion Corouge, Alexandre Louvet, Stanislas Pol, Philippe Sogni, Amine Benyamina, Jürgen Rehm, Philippe Mathurin, Vincent Mallet
Journal: Clinical Gastroenterology and Hepatology (2024)
Accuracy of Computer-aided Diagnosis in Colonoscopy Varies According to Polyp Location: A Systematic Review and Meta-analysis
Authors: Tommy Rizkala, Cesare Hassan, Yuichi Mori, Marco Spadaccini, Giulio Antonelli, Evelien Dekker, Britt B.S.L. Houwen, Oliver Pech, Sebastian Baumer, Emanuele Rondonotti, Franco Radaelli, James Weiquan Li, Daniel von Renteln, Masashi Misawa, Antonio Facciorusso, Roberta Maselli, Silvia Carrara, Alessandro Fugazza, Antonio Capogreco, Kareem Khalaf, Harsh Patel, Prateek Sharma, Douglas Rex, Alessandro Repici
Journal: Clinical Gastroenterology and Hepatology (2024)